ReviewFrontiers in psychiatry2026
Clinical and cognitive insight in schizophrenia and their relationship with neurocognition and metacognition: a narrative review.
Review in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Impaired insight in schizophrenia is consistently associated with poorer treatment adherence, more frequent hospitalization, and worse functional outcomes, yet the cognitive mechanisms that account for impaired insight remain incompletely specified. The neurocognitive model has long been the dominant explanatory framework but accounts for only a small fraction of the variance in clinical insight. This review synthesizes evidence on clinical and cognitive insight in relation to neurocognition and metacognition, identifies integrative metacognition as the principal explanatory bridge between basic cognitive resources and illness awareness, and develops the translational implications of this organization. Insight is treated as a multidimensional construct that includes clinician-rated awareness of illness and the metacognitive evaluation of one's own beliefs. Metacognition is shown to encompass distinct construct families with different bearings on insight, of which the integrative tradition shows the most theoretically central and empirically robust associations with clinical insight. Converging but largely indirect evidence is consistent with a multi-factor model in which integrative metacognition is hypothesized to partially mediate the relationship between neurocognition and clinical insight, while cognitive insight functions as an adjacent construct that overlaps with but does not exhaust metacognitive variance. The insight paradox is incorporated as a structural feature of the model, with internalized stigma possibly moderating whether heightened awareness translates into adaptive engagement or into depression and reduced quality of life. Interventions that target metacognitive processes, including Metacognitive Training and Metacognitive Reflection and Insight Therapy, produce measurable improvements in insight outcomes, whereas approaches without explicit metacognitive targets show limited and inconsistent effects. Longitudinal designs, mediation-focused intervention trials, and the integration of emerging candidate mechanisms such as mental time travel are proposed as priorities for consolidating the model. Literature was identified through searches of PubMed, PsycINFO, Embase, Web of Science, and Scopus up to May 2026, focusing on recent peer-reviewed work in adult schizophrenia-spectrum populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.